Tranexamic Acid to Prevent Bleeding in Myelodysplastic Syndromes and Leukemia
Tests tranexamic acid against placebo to prevent bleeding in adults with blood cancers.
Plain-language title generated from the registry record
Registry title: Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Key facts
- Where
- Winnipeg, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- CancerCare ManitobaWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Manitoba
- Trial code
- NCT06599762
- Record updated
- 22 April 2026
- Original description
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and/or severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.Read full original descriptionShow less
Evaluation of Tranexamic Acid Among Outpatients With Myelodysplastic Syndromes and Acute Myeloid Leukemia: a Multicenter Pilot Trial
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and/or severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.
Inclusion: Master platform inclusion criteria:; Age ≥ 18 years; Diagnosis of myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm or acute myeloid leukemia; MYELO-CAN TXA inclusion criteria:; Receipt of less-intensive chemotherapy (includes both frontline and relapsed/refractory setting); Severe thrombocytopenia (platelets ≤ 30x10\^9/L or platelets ≤ 50x10\^9/L prior to chemotherapy initiation).
Exclusion: Known allergy to tranexamic acid; Active thromboembolic disease; Active ischemic heart disease; Stage V chronic kidney disease; Master platform exclusion criteria:; Participant is deemed unlikely to survive >30 days (as determined by clinical team); Participant unable to provide informed consent; MYELO-CAN TXA exclusion criteria:; Gross hematuria; Clinically suspected disseminated intravascular coagulation (DIC); Pregnancy and/or breastfeeding.